RU58841 vs. Finasterid
Was ist das Richtige für Sie? Vollständiger Vergleich (2026)
Vergleich zwischen dem topischen RU58841 und dem oralen Klassiker Finasterid gegen erblichen Haarausfall.
RU58841 vs. Finasterid: Auf einen Blick
- ✓Topischer Androgenrezeptor-Antagonist
- ✓Blockiert DHT direkt am Haarfollikel
- ✓Minimale systemische Aufnahme
- ✓Keine finale klinische Zulassung
- ✓Beliebt in der Off-Label-Community
- ✓Zugelassener 5-Alpha-Reduktase-Hemmer
- ✓Senkt Serum-DHT um ~70 %
- ✓Orales Medikament (1 mg täglich)
- ✓Umfangreiche Langzeitdaten (25+ Jahre)
- ✓Kann systemische Nebenwirkungen haben
Detailed Comparison
| Feature | Ru58841 | Finasteride |
|---|---|---|
| Mechanism | Non-steroidal antiandrogen | 5-alpha reductase inhibitorBest |
| Dosing | 25-50 mg in topical solution daily | 1 mg orally daily (hair loss); 5 mg daily (BPH) |
| Administration | Topical | Oral |
| Half-life | Topical — local effect | ~6-8 hours |
| FDA Status | Not FDA-approved — abandoned research compound | FDA-approved (Propecia, Proscar) |
| Key Trial | Battmann T et al. J Steroid Biochem Mol Biol 1994 — characterization | Kaufman KD et al. JAAD 1998 — 5-year efficacy data |
| Side Effects | Scalp irritation; unknown long-term safety (no completed trials) | Sexual dysfunction (1-2%), gynecomastia, depression (rare) |
Which Should You Choose?
RU58841 (non-steroidal antiandrogen) and Finasteride (5-alpha reductase inhibitor) serve different clinical roles despite both being in the Hair loss compound space. RU58841 topical non-steroidal antiandrogen that blocks dht binding to androgen receptors in hair follicles without systemic anti-androgenic effects. Finasteride competitive inhibitor of type ii 5-alpha reductase that reduces dht conversion by ~70%, slowing androgenetic alopecia and shrinking prostate.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Ru58841 and Finasteride
Choosing between Ru58841 and Finasteride depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Ru58841 and Finasteride is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Ru58841 vs Finasteride: Häufig gestellte Fragen
RU58841 wirkt lokal und hat daher seltener sexuelle Nebenwirkungen als orales Finasterid, ist aber weniger erforscht.
Ru58841 oder Finasteride in Shotlee tracken
Kostenloses Dosis-Tracking, Protokollierung von Nebenwirkungen und Ergebnisvergleich für jedes Medikamentenprotokoll.